An atlas of genetic influences on human blood metabolites

Shin et al., Nature Genetics, 2014 [ Article | SI Text ]

Locus 55: SLC22A1|SLC22A2 (6q25.3)

Meta-analysis summary statistics for associations meeting genome-wide significance
Lead SNPBiochemicalsEA/OANtotalEAFEffect (SE)PmetaDetails
rs662138 isobutyrylcarnitine C/G 7365 0.83 0.077 (0.005) 4.98·10-49 show
rs662138 X-11261 C/G 7322 0.83 0.063 (0.006) 9.38·10-25 show
rs662138 X-03056--N-[3-(2-oxopyrrolidin-1-yl)propyl]acetamide C/G 7363 0.83 0.034 (0.004) 1.04·10-22 show
rs662138 propionylcarnitine C/G 7364 0.83 0.021 (0.003) 3.15·10-14 show

EA = effect allele; OA = other allele; EAF = frequency of effect allele;

Summary of biological annotations
SNPrs662138
Chromosomal locationChr6: 160,484,466 (6q25.3)
Gene (distance)SLC22A1 (0)
Predicted causal geneSLC22A1
Gene/protein classificationtransporter/transporter
Metabolite (Pathway)isobutyrylcarnitine (Valine, leucine and isoleucine metabolism; Amino acid)
Biochemical locus-metabolite relationshipSLC22A1 and SLC22A2 encode the Oct1 and Oct2 organic cation transporters. Perhaps isobutyrylcarnitine or a related metabolite is a substrate [9260930].
eQTL associations-

 

Medical information
Complex trait associationsCholesterol, total [20686565]; LDL cholesterol [20686565]
Known metabolite associationsisobutyrylcarnitine [21886157]
Inborn error of metabolism-

Pharmacological information
ChEMBL IDCHEMBL5685, CHEMBL1743122
Drug information Substrates of SLC22A1: Tetraethylammonium, N-methylpyridinium, metformin*, oxaliplatin; Inhibitors of SLC22A1: Quinine, quinidine, disopyramide; Substrates of SLC22A2: N-Methylpyridinium, tetraethylammonium, metformin*, pindolol, procainamide, ranitidine amantadine, amiloride, oxaliplatin, varenicline; Inhibitors of SLC22A2: Cimetidine*, pilsicainide, cetirizine*, testosterone, quinidine; (PMID: 20190787)

Locus information for top associated metabolite

HapMap2 imputation

Imputation HapMap

1KGP imputation

Imputation 1KGP

 

Network view
Association map